Biomedical Science Clinical Trials Biomedical Science RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
Condition:   NHL Intervention:   Drug: IM19 CAR-T Cells Sponsor:   Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 19, 2020 Category: Research Source Type: clinical trials